WO2001070984A3 - Anti-tissue factor antibodies with enhanced anticoagulant potency - Google Patents

Anti-tissue factor antibodies with enhanced anticoagulant potency Download PDF

Info

Publication number
WO2001070984A3
WO2001070984A3 PCT/US2001/007501 US0107501W WO0170984A3 WO 2001070984 A3 WO2001070984 A3 WO 2001070984A3 US 0107501 W US0107501 W US 0107501W WO 0170984 A3 WO0170984 A3 WO 0170984A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue factor
antibodies
factor antibodies
enhanced anticoagulant
anticoagulant potency
Prior art date
Application number
PCT/US2001/007501
Other languages
French (fr)
Other versions
WO2001070984A2 (en
Inventor
Daniel K Kirchhofer
David G Lowe
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU5081401A priority Critical patent/AU5081401A/en
Priority to AU2001250814A priority patent/AU2001250814B2/en
Priority to JP2001569367A priority patent/JP2003527861A/en
Priority to EP01924131A priority patent/EP1263960A2/en
Priority to CA002402596A priority patent/CA2402596A1/en
Publication of WO2001070984A2 publication Critical patent/WO2001070984A2/en
Publication of WO2001070984A3 publication Critical patent/WO2001070984A3/en
Priority to HK03101227.0A priority patent/HK1049184A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention concerns anti-tissue factor (anti-TF) antibodies with enhanced anticoagulant potency, and methods and means for identifying, producing and using such antibodies. The anti-TF antibodies of the present invention are designed to comprise a region binding to an epitope in the C-terminal macromolecular substrate binding region of TF.
PCT/US2001/007501 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency WO2001070984A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU5081401A AU5081401A (en) 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency
AU2001250814A AU2001250814B2 (en) 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency
JP2001569367A JP2003527861A (en) 2000-03-16 2001-03-08 Anti-tissue factor antibody with enhanced anticoagulant ability
EP01924131A EP1263960A2 (en) 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency
CA002402596A CA2402596A1 (en) 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency
HK03101227.0A HK1049184A1 (en) 2000-03-16 2003-02-18 Anti-tissue factor antibodies with enhanced anticoagulant potency

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18977500P 2000-03-16 2000-03-16
US60/189,775 2000-03-16

Publications (2)

Publication Number Publication Date
WO2001070984A2 WO2001070984A2 (en) 2001-09-27
WO2001070984A3 true WO2001070984A3 (en) 2002-02-28

Family

ID=22698717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007501 WO2001070984A2 (en) 2000-03-16 2001-03-08 Anti-tissue factor antibodies with enhanced anticoagulant potency

Country Status (6)

Country Link
EP (1) EP1263960A2 (en)
JP (1) JP2003527861A (en)
AU (2) AU2001250814B2 (en)
CA (1) CA2402596A1 (en)
HK (1) HK1049184A1 (en)
WO (1) WO2001070984A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT833911E (en) 1995-06-07 2004-09-30 Ortho Mcneil Pharm Inc ANTI-FACTOR ANTI-FACTOR ANTI-FACTOR CUTTED WITH CDR AND METHODS FOR THEIR USE
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2002078738A1 (en) * 2001-03-26 2002-10-10 Koji Suzuki Blood rheology improving agents
MXPA04003051A (en) * 2001-10-02 2004-07-05 Novo Nordisk As Human tissue factor antibodies.
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
KR20050004785A (en) * 2002-02-22 2005-01-12 프롭휘 메드 아베 Use of an inhibitor or antagonist against tissue factor
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
UA85996C2 (en) * 2002-05-01 2009-03-25 Шеринг Акциенгезельшафт Tissue factor targeted thrombomodulin fusion proteins as anticoagulants
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
AU2003275947A1 (en) * 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CA2515081A1 (en) * 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2004075913A1 (en) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
KR20060035608A (en) * 2003-05-30 2006-04-26 센토코 인코포레이티드 Method of inhibiting tumor growth with anti-tissue factor antibodies
WO2005000896A2 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
KR100912381B1 (en) * 2003-06-19 2009-08-19 타녹스 인코퍼레이티드 Compositions and methods for treating coagulation related disorders
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
PL2993186T3 (en) 2008-03-14 2020-02-28 Biocon Limited A monoclonal antibody and a method thereof
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
JP6055404B2 (en) 2010-06-15 2016-12-27 ゲンマブ エー／エス Human antibody drug conjugates against tissue factor
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
MX371272B (en) 2013-03-15 2020-01-22 Univ California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival.
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
JP5957637B2 (en) * 2014-02-03 2016-07-27 国立研究開発法人国立がん研究センター Anti-TissueFactor monoclonal antibody
AU2017344462A1 (en) 2016-10-21 2019-05-02 Biocon Limited A monoclonal antibody and a method of use for the treatment of lupus
TW201922796A (en) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
BR112023000455A2 (en) * 2020-07-10 2023-03-28 Iconic Therapeutics Inc TREATMENT OF INFLAMMATORY DISEASE USING ANTI-TISSUE FACTOR ANTIBODIES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811248A (en) * 1986-03-31 1998-09-22 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
WO1999051743A1 (en) * 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596065A (en) * 1897-12-28 Ejector for ashes
DE3237880A1 (en) * 1982-10-13 1984-04-19 Robert Bosch Gmbh, 7000 Stuttgart CODE STORAGE, ESPECIALLY FOR WORKPIECE CARRIERS IN FLOW MANUFACTURING
JPS60188045A (en) * 1984-03-08 1985-09-25 リサーチ・コーポレイシヨン Storage stable fish meat paste product

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811248A (en) * 1986-03-31 1998-09-22 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
WO1999051743A1 (en) * 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
EP1069185A1 (en) * 1998-04-03 2001-01-17 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KIRCHHOFER D ET AL: "ANTICOAGULANT ACTIVITY OF DIFFERENT TISSUE FACTOR/FACTOR VIIA INHIBITORS IN A HUMAN EX-VIVO THROMBOSIS MODEL", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 86, no. 10, SUPPL 1, 15 November 1995 (1995-11-15), pages 91A, XP002028014, ISSN: 0006-4971 *
KIRCHHOFER D ET AL: "MOLECULAR AND STRUCTURAL ADVANCES IN TISSUE FACTOR-DEPENDENT COAGULATION", TRENDS IN CARDIOVASCULAR, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 7, no. 8, November 1997 (1997-11-01), pages 316 - 324, XP000985403, ISSN: 1050-1738 *
KIRCHHOFER DANIEL ET AL: "Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies.", THROMBOSIS AND HAEMOSTASIS, vol. 84, no. 6, December 2000 (2000-12-01), pages 1072 - 1081, XP001041490, ISSN: 0340-6245 *
PRESTA LEONARD ET AL: "Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic.", THROMBOSIS AND HAEMOSTASIS, vol. 85, no. 3, March 2001 (2001-03-01), pages 379 - 389, XP001041497, ISSN: 0340-6245 *
REFINO CANIO J ET AL: "A human antibody that binds to the gamma-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo.", THROMBOSIS AND HAEMOSTASIS, vol. 82, no. 3, 1999, pages 1188 - 1195, XP001041486, ISSN: 0340-6245 *
See also references of EP1263960A2 *

Also Published As

Publication number Publication date
JP2003527861A (en) 2003-09-24
AU5081401A (en) 2001-10-03
WO2001070984A2 (en) 2001-09-27
AU2001250814B2 (en) 2007-02-15
CA2402596A1 (en) 2001-09-27
EP1263960A2 (en) 2002-12-11
HK1049184A1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
DK1259547T3 (en) HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
WO2005007809A3 (en) Antibodies and fusion proteins that include engineered constant regions
WO2002024149A3 (en) Immunogen comprising ligand bound hiv envelpe protein
WO2004029207A3 (en) Optimized fc variants and methods for their generation
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
WO2002057293A3 (en) Modified zinc finger binding proteins
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2004020405A3 (en) Modified transferrin fusion proteins
WO2002002636A3 (en) Membrane associated protein zupari
IL166632A (en) Antibody that binds an alpha-fetoprotein antigen and fusion protein comprising such
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
WO2003029458A3 (en) Method for producing protein libraries and for selecting proteins from said libraries
EP1308507A3 (en) HCV anti-core monoclonal antibodies
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2003025019A8 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
WO2004009785A3 (en) IgG Fc/HIV-gp120/C3d FUSION PROTEIN
AU2001239921A1 (en) Antibody inhibiting the binding between GP120 and DC-SIGN and screening methods
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
WO2001085792A3 (en) Mu-1, member of the cytokine receptor family
WO2003040341A3 (en) Anti-hepatitis a virus antibodies
WO2003020759A3 (en) A caspase- 8 binding protein, its preparation and use
WO2003046137A3 (en) Hiv envelope v3-ccr5 binding site immunogen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001250814

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2402596

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 569367

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001924131

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001924131

Country of ref document: EP